Avicanna To Hold Third Quarter 2023 Earnings Conference Call
November 01 2023 - 4:55PM
Avicanna Inc. (“
Avicanna” or
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a biopharmaceutical company focused on the development,
manufacturing, and commercialization of plant-derived
cannabinoid-based products, invites interested parties to
participate in a conference call with Aras Azadian, Chief Executive
Officer, and also Phil Cardella, Chief Financial Officer where Mr.
Azadian and Mr. Cardella will discuss the Company’s Third Quarter
2023 financial results. The Company will file Third Quarter 2023
financial results after the close of market on November 14, 2023
and will host an earnings call at 8:30 am ET on November 15, 2023.
Interested parties may join the earnings call by logging onto the
following link
https://www.bigmarker.com/avicanna/Earnings-Call.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments and
delivering a comprehensive medical cannabis care platform in
Canada. Avicanna has an established scientific platform including
R&D and clinical development that has led to the
commercialization of more than thirty products across various
market segments:
- Medical Cannabis &
Wellness Products (RHO
Phyto™): The
formulary offers a diverse range of proprietary formulations
including oral, sublingual, topical, and transdermal deliveries
with varying ratios of cannabinoids and is supported with ongoing
patient, and medical community education. RHO Phyto has been
established as a leading medical brand in Canada and is currently
available nationwide to patients across several medical channels
and continues to expand into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive a pipeline of patent-pending
drug candidates that are indication-specific and in various stages
of clinical development and commercialization. These
cannabinoid-based drug candidates look to address unmet medical
needs in the areas of dermatology, chronic pain, and various
neurological disorders. Avicanna’s first pharmaceutical preparation
(Trunerox™) is in the drug registration stage in South
America.
- MyMedi.ca
Medical Cannabis Care: MyMedi.ca
is Avicanna’s medical cannabis care platform that is formed with
the aim to better serve medical cannabis patients’ needs and
enhance the patient journey. MyMedi.ca features diverse and
scientifically curated products from leading Canadian licensed
producers in addition to pharmacist-led and bilingual patient
support programs with educational resources to facilitate the
incorporation of medical cannabis into health care regimens.
MyMedi.ca also provides specialty services to distinct patient
groups such as veterans and collaborates with public and private
providers for adjudication and reimbursement.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media on LinkedIn, Twitter, Facebook or
Instagram.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking information contained in this
news release includes, without limitation, statements related to
the Offering, including the use of proceeds, the receipt of all
approvals of the Toronto Stock Exchange in connection with the
Offering, statements with respect to the Company's future business
operations, the opinions or beliefs of management and future
business goals. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include, but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 and final short form prospectus dated November 27,
2020, filed with the Canadian securities regulators and available
under the Company’s profile on SEDAR at www.sedar.com. The
statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Avicanna (TSX:AVCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
From Apr 2023 to Apr 2024